Your browser doesn't support javascript.
loading
Treatment of chronic or relapsing COVID-19 in immunodeficiency.
Brown, Li-An K; Moran, Ed; Goodman, Anna; Baxendale, Helen; Bermingham, William; Buckland, Matthew; AbdulKhaliq, Iman; Jarvis, Hannah; Hunter, Michael; Karanam, Surendra; Patel, Aisha; Jenkins, Megan; Robbins, Alexander; Khan, Sujoy; Simpson, Thomas; Jolles, Stephen; Underwood, Jonathan; Savic, Sinisa; Richter, Alex; Shields, Adrian; Brown, Michael; Lowe, David M.
Affiliation
  • Brown LK; Institute of Immunity and Transplantation, University College London, London, United Kingdom; University College London Hospital NHS Foundation Trust, London, United Kingdom.
  • Moran E; North Bristol NHS Trust, Bristol, United Kingdom.
  • Goodman A; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.
  • Baxendale H; Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.
  • Bermingham W; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Buckland M; Barts Health, London, United Kingdom; Institute of Child Health, University College London and Great Ormond Street Hospital, London, United Kingdom.
  • AbdulKhaliq I; Mid and South Essex NHS Foundation Trust, Essex, United Kingdom.
  • Jarvis H; Royal Free London NHS Foundation Trust, London, United Kingdom.
  • Hunter M; Royal Victoria Hospital, Belfast, United Kingdom.
  • Karanam S; Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom.
  • Patel A; University College London Hospital NHS Foundation Trust, London, United Kingdom.
  • Jenkins M; North Bristol NHS Trust, Bristol, United Kingdom.
  • Robbins A; Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Khan S; Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom.
  • Simpson T; Lewisham and Greenwich NHS Trust, London, United Kingdom.
  • Jolles S; University Hospital of Wales, Cardiff, United Kingdom.
  • Underwood J; Department of Infectious Diseases, Cardiff and Vale University Health Board, Cardiff, United Kingdom; Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom.
  • Savic S; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.
  • Richter A; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Shields A; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Brown M; University College London Hospital NHS Foundation Trust, London, United Kingdom; Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Lowe DM; Institute of Immunity and Transplantation, University College London, London, United Kingdom; Royal Free London NHS Foundation Trust, London, United Kingdom. Electronic address: d.lowe@ucl.ac.uk.
J Allergy Clin Immunol ; 149(2): 557-561.e1, 2022 02.
Article in En | MEDLINE | ID: mdl-34780850
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Alanine / SARS-CoV-2 / COVID-19 / Immunologic Deficiency Syndromes / Antibodies, Monoclonal Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Alanine / SARS-CoV-2 / COVID-19 / Immunologic Deficiency Syndromes / Antibodies, Monoclonal Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2022 Type: Article